Following the cue of the medical arena as a whole, the medical aesthetic and dermatology fields are inexorably turning towards progressive, all-inclusive therapies. This approach combines various integrative clinical techniques that address the patient’s complete well-being, including adjunctive skincare regimens.
In medical aesthetics, transdermal devices, or penetration enhancers, that use microneedles, rollers, dermoelectroporation and other novel modalities offer practitioners an efficient and minimally invasive technique to penetrate the skin barrier. But while practitioners have eagerly embraced these products and devices, few therapeutic or regulatory standards exist.
Biotechnology company Revance Therapeutics, Inc. (Newark, Calif.) recently published the results of two pivotal trials of the company's neurotoxin drug candidate DaxibotulinumtoxinA for Injection (RT002), intended for the treatment of moderate to severe glabellar lines in adults. Based on these study findings, Revance announced that it expects U.S. FDA approval in 2019 and approval in Europe in 2021.
The U.S. aesthetic neurotoxin marketplace is set to expand somewhat dramatically in 2019.
With great regret we acknowledge the passing of Vic A. Narurkar, M.D., F.A.A.D., an internationally known, board-certified dermatologist and dermatologic surgeon from San Francisco, Calif.
In the medical world, the provider-patient relationship is one of shared decision making based on the principles of mutual trust, ethics and appropriate attention to needs. This guidance is of especially high value in an aesthetic practice, where the patient electively wants to achieve an enhanced appearance and improved quality of life based on physician guidance.
Sharing practice videos and patient photos in the office and online can be a vital marketing tool for aesthetic physicians. However, you need to ensure conformity with the regulations set down in the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which were designed to protect the privacy and security of certain health information.
Across Europe, physicians and patients are discovering that ThermiVa® from Thermi, an Almirall company (Dallas, Texas, U.S.), fulfills an unmet need in the areas of aesthetics and medical vaginal health. Invasive procedures like labiaplasty and vaginoplasty, along with bladder and prolapse surgeries, typically require lengthy and oftentimes painful recoveries, as well as serious complications. With the ThermiVa, women now have a non-surgical option.
A fast, no-downtime fat reduction treatment for the submental region has finally arrived. SculpSure®, the efficient laser-based body contouring platform from Hologic, Inc. (Marlborough, Mass.), which also treats the abdomen, flanks, back, and inner and outer thighs, was recently FDA-cleared to address the double chin.
One does not need surgery or energy-based devices to achieve the best facial rejuvenation treatment outcomes. In performing minimally invasive facial rejuvenation, the tools of the trade are numerous: dermal fillers, neurotoxins, collagen stimulating lifting threads; platelet-rich plasma (PRP) delivered transdermally via needle, microneedle or cannula; fat transfer and more.